Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NG-641
- Development stage
- Phase 1
- Lead developer
- Akamis Bio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
NG-641 is an experimental oncolytic adenoviral vector engineered to selectively infect and replicate in tumor cells. It encodes four immunostimulatory transgenes: a fibroblast activation protein (FAP)-directed bispecific T-cell activator antibody (FAP-TAc), interferon alpha (IFNα), and the chemokines CXCL9 and CXCL10. The FAP-targeted bispecific antibody redirects T cells to attack cancer-associated fibroblasts within the tumor microenvironment, while IFNα and the chemokines enhance immune cell recruitment and activation. This multi-pronged approach aims to remodel the tumor microenvironment for improved anti-tumor immunity. Developed by Akamis Bio (formerly PsiOxus Therapeutics), NG-641 is being investigated primarily for solid tumors including squamous cell carcinoma of the head and neck in early-phase clinical trials[1][2][3][4][5][6][7][8].
- Other names
- enadenotucirev-expressing FAP/CD3 bispecific FAP-TAc NG-641
02
Targets
FAP (Fibroblast activation protein alpha)CCR3 (C-C chemokine receptor type 3)IFNAR (Immune system modulation via type I interferon receptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on NG-641.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NG-641.